The market for BCMA-targeted therapies is expected to grow significantly in the coming years. This is due to the increasing number of patients who are being diagnosed with cancer, the growing awareness of BCMA-targeted therapies, the increasing number of BCMA-targeted therapies that are under clinical trials, and the increasing interest of major pharmaceutical companies toward it. LAS VEGAS , Aug.
21, 2024 /PRNewswire/ -- DelveInsight's BCMA-Targeted Therapies Market Insights report includes a comprehensive understanding of current treatment practices, emerging BCMA-targeted therapies, market share of individual therapies, and current and forecasted BCMA-targeted therapies market size from 2020 to 2034, segmented into 7MM [ the United States , the EU-4 ( Italy , Spain , France , and Germany ), the United Kingdom , and Japan ]. Key Takeaways from the BCMA-Targeted Therapies Market Report As per DelveInsight's analysis, the current market size of BCMA-targeted therapies is anticipated to grow significantly in the 7MM by 2034. Leading BCMA-targeted therapy companies such as Poseida Therapeutics, Roche, CARsgen Therapeutics, Novartis, and others are developing novel BCMA-targeted therapies that can be available in the BCMA-targeted therapies market in the coming years.
Some of the key BCMA-targeted therapies include Zevor-cel/zevorcabtagene autoleucel (CT053), P-BCMA-ALLO1 , and others. In February 2024 , AstraZeneca finalized its acquisition of Gracell Biotechnologie for around .